DK1509232T3 - Kombination af en NMDA-antagonist og acetylcholin-esterase inhibitorer til behandling af Alzheimers sygdom - Google Patents

Kombination af en NMDA-antagonist og acetylcholin-esterase inhibitorer til behandling af Alzheimers sygdom

Info

Publication number
DK1509232T3
DK1509232T3 DK03724895T DK03724895T DK1509232T3 DK 1509232 T3 DK1509232 T3 DK 1509232T3 DK 03724895 T DK03724895 T DK 03724895T DK 03724895 T DK03724895 T DK 03724895T DK 1509232 T3 DK1509232 T3 DK 1509232T3
Authority
DK
Denmark
Prior art keywords
disease
combination
acetylcholine esterase
nmda antagonist
treat alzheimer
Prior art date
Application number
DK03724895T
Other languages
Danish (da)
English (en)
Inventor
Lars Lykke Thomsen
Anders Gersel Pedersen
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29713304&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1509232(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Application granted granted Critical
Publication of DK1509232T3 publication Critical patent/DK1509232T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK03724895T 2002-05-31 2003-05-22 Kombination af en NMDA-antagonist og acetylcholin-esterase inhibitorer til behandling af Alzheimers sygdom DK1509232T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38446702P 2002-05-31 2002-05-31
DKPA200200844 2002-05-31
PCT/DK2003/000342 WO2003101458A1 (en) 2002-05-31 2003-05-22 A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease

Publications (1)

Publication Number Publication Date
DK1509232T3 true DK1509232T3 (da) 2009-02-23

Family

ID=29713304

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03724895T DK1509232T3 (da) 2002-05-31 2003-05-22 Kombination af en NMDA-antagonist og acetylcholin-esterase inhibitorer til behandling af Alzheimers sygdom

Country Status (17)

Country Link
EP (1) EP1509232B1 (de)
JP (1) JP2005528431A (de)
AT (1) ATE414519T1 (de)
AU (1) AU2003227516B2 (de)
BR (1) BR0311375A (de)
CY (1) CY1108725T1 (de)
DE (1) DE60324788D1 (de)
DK (1) DK1509232T3 (de)
ES (1) ES2314200T3 (de)
IL (1) IL165255A0 (de)
MX (1) MXPA04011762A (de)
NO (1) NO332754B1 (de)
NZ (1) NZ536603A (de)
PL (1) PL373903A1 (de)
PT (1) PT1509232E (de)
SI (1) SI1509232T1 (de)
WO (1) WO2003101458A1 (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200418446A (en) * 2002-10-24 2004-10-01 Merz Pharma Gmbh & Co Kgaa Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors
WO2005067908A2 (en) * 2004-01-05 2005-07-28 Merz Pharma Gmbh & Co. Kgaa Memantine for the treatment of mild and mild-to-moderate alzheimer’s disease
EP1708707A1 (de) * 2004-01-22 2006-10-11 Neurosearch A/S Pharmazeutische zusammensetzung mit einem monoamin-neurotransmitter-wiederaufnahmehemmer und einem n-methyl-d-aspartat (nmda)-rezeptorantagonisten
TW200531680A (en) * 2004-03-03 2005-10-01 Merz Pharma Gmbh & Co Kgaa Therapy using 1-aminocyclohexane derivatives for the treatment of behavioral disorders associated with alzheimer's disease
JP2007529556A (ja) * 2004-03-19 2007-10-25 アクソニクス インコーポレイテッド 認知障害の処置に有用なアセチルコリンエステラーゼ阻害剤およびｎ−メチル−ｄ−アスパラギン酸拮抗剤
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
CA2588295C (en) * 2004-11-23 2013-10-22 Adamas Pharma, Llc Method and composition for administering an nmda receptor antagonist to a subject
ATE481096T1 (de) 2005-04-06 2010-10-15 Adamas Pharmaceuticals Inc Verfahren und zusammensetzungen zur behandlung von zns-erkrankungen
CN101166543B (zh) * 2005-04-28 2014-07-16 卫材R&D管理有限公司 含抗痴呆药物的组合物
TWI389709B (zh) * 2005-12-01 2013-03-21 Novartis Ag 經皮治療系統
US8278345B2 (en) 2006-11-09 2012-10-02 Probiodrug Ag Inhibitors of glutaminyl cyclase
ATE554085T1 (de) 2006-11-30 2012-05-15 Probiodrug Ag Neue inhibitoren von glutaminylcyclase
JP5930573B2 (ja) 2007-03-01 2016-06-15 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤の新規使用
EP2142514B1 (de) 2007-04-18 2014-12-24 Probiodrug AG Thioharnstoffderivate als glutaminylcyclaseinhibitoren
JP5934645B2 (ja) 2009-09-11 2016-06-15 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのヘテロ環式誘導体
RU2414856C1 (ru) * 2009-12-01 2011-03-27 Государственное образовательное учреждение высшего профессионального образования Первый Московский медицинский университет имени И.М.Сеченова Министерства здравоохранения и социального развития Российской Федерации (ГОУ ВПО Первый МГМУ им. И.М.Сеченова Минздравсоцразвития России) Способ определения эффективности противодементной терапии болезни альцгеймера
CA2994873A1 (en) 2009-12-02 2011-06-09 Adamas Pharma, Llc Amantadine compositions and methods of use
AU2011215870B2 (en) 2010-02-09 2016-01-28 The Johns Hopkins University Methods and compositions for improving cognitive function
JP6026284B2 (ja) 2010-03-03 2016-11-16 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤
NZ602312A (en) 2010-03-10 2014-02-28 Probiodrug Ag Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
WO2011131748A2 (en) 2010-04-21 2011-10-27 Probiodrug Ag Novel inhibitors
KR101862425B1 (ko) 2010-07-05 2018-05-29 감브로 룬디아 아베 이동식 한외 여과 장치，관련 방법 및 컴퓨터 프로그램 제품
TR201007110A2 (tr) 2010-08-25 2012-03-21 Bi̇lgi̇ç Mahmut Sinerjik etki gösteren kombinasyonlar
WO2012048871A1 (en) 2010-10-12 2012-04-19 Merz Pharma Gmbh & Co. Kgaa Memantine for improving cognitive performance in subjects
EP2686313B1 (de) 2011-03-16 2016-02-03 Probiodrug AG Benzimidazolderivate als glutaminylcyclase-hemmer
FR2983732B1 (fr) * 2011-12-09 2013-11-22 Servier Lab Nouvelle association entre le 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1h)-yl]propoxy}pharmaceutiques qui la contiennent
WO2013160728A1 (en) * 2012-04-26 2013-10-31 Alma Mater Studiorum - Universita' Di Bologna Dual targeting compounds for the treatment of alzheimer's disease
WO2014035355A1 (en) * 2012-08-31 2014-03-06 Mahmut Bilgic Pharmaceutical combination comprising idebenone and memantine
WO2014055047A1 (en) * 2012-08-31 2014-04-10 Mahmut Bilgic Combination of idebenone and donezepil
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
PL2931276T3 (pl) * 2012-12-13 2018-06-29 H. Lundbeck A/S Kompozycje zawierające wortioksetynę i donepezil
WO2014144663A1 (en) 2013-03-15 2014-09-18 The Johns Hopkins University Methods and compositions for improving cognitive function
JP6433482B2 (ja) 2013-03-15 2018-12-05 エージンバイオ， インコーポレイテッド 認知機能を改善するための方法および組成物
US10154971B2 (en) 2013-06-17 2018-12-18 Adamas Pharma, Llc Methods of administering amantadine
WO2016191288A1 (en) 2015-05-22 2016-12-01 Agenebio, Inc. Extended release pharmaceutical compositions of levetiracetam
DK3458039T3 (da) 2016-05-18 2020-09-14 Suven Life Sciences Ltd Tripelkombination af rene 5-ht6-receptorantagonister, acetylcholinesterasehæmmere og nmda-receptorantagonist
JP7073330B2 (ja) 2016-07-25 2022-05-23 ウィスタ ラボラトリーズ リミテッド ジアミノフェノチアジンの投与及び投与量
GB201614834D0 (en) * 2016-09-01 2016-10-19 Wista Lab Ltd Treatment of dementia
KR101938872B1 (ko) * 2016-09-30 2019-01-16 주식회사 바이오파마티스 도네페질 또는 그의 약학적으로 허용 가능한 염 및 메만틴 또는 그의 약학적으로 허용 가능한 염을 함유하는 치매 및 인지기능 장애 예방 또는 치료용 약학 조성물 및 이의 제조방법
WO2018081508A1 (en) * 2016-10-28 2018-05-03 Chase Pharmaceutical Corporation Memantine combinations and use
TR201619184A2 (tr) 2016-12-22 2018-07-23 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Donepezi̇l ve memanti̇n i̇çeren kapsül bi̇leşi̇mleri̇
AU2018320946B2 (en) 2017-08-24 2024-05-02 Adamas Pharma, Llc Amantadine compositions, preparations thereof, and methods of use
ES2812698T3 (es) 2017-09-29 2021-03-18 Probiodrug Ag Inhibidores de glutaminil ciclasa
FI4385512T3 (fi) 2018-07-26 2026-01-12 Taurx Therapeutics Man Ltd Diaminofenotiatsiinien optimoitu annostus populaatioille
BR112021024054A2 (pt) 2019-05-31 2022-01-11 Tecnimede Sociedade Tecnico Medicinal Sa Composições farmacêuticas de combinação de dose fixa de liberação imediata, seus métodos e usos.

Also Published As

Publication number Publication date
NO332754B1 (no) 2013-01-07
SI1509232T1 (sl) 2009-04-30
WO2003101458A1 (en) 2003-12-11
IL165255A0 (en) 2005-12-18
CY1108725T1 (el) 2014-04-09
ATE414519T1 (de) 2008-12-15
NO20045434L (no) 2004-12-13
MXPA04011762A (es) 2005-03-31
ES2314200T3 (es) 2009-03-16
EP1509232B1 (de) 2008-11-19
PL373903A1 (en) 2005-09-19
AU2003227516B2 (en) 2008-03-20
DE60324788D1 (de) 2009-01-02
AU2003227516A1 (en) 2003-12-19
NZ536603A (en) 2007-06-29
EP1509232A1 (de) 2005-03-02
JP2005528431A (ja) 2005-09-22
BR0311375A (pt) 2005-03-15
PT1509232E (pt) 2009-01-07

Similar Documents

Publication Publication Date Title
DK1509232T3 (da) Kombination af en NMDA-antagonist og acetylcholin-esterase inhibitorer til behandling af Alzheimers sygdom
BR0308243A (pt) Composto, formulação farmacêutica, e, métodos de tratar diabetes, doença de alzheimer, e de inibir gsk-3 em um mamìfero
PL361404A1 (en) Synergistic combinations comprising a renin inhibitor for cardiovascular diseases
DK1257550T3 (da) Blodplade-ADP-receptor-inhibitor
BRPI0407993B8 (pt) compostos inibidores de p38 e composições farmacêuticas compreendendo os mesmos
DE60332433D1 (de) Azolylaminoazine als proteinkinasehemmer
DE60332604D1 (de) Azolylaminoazine als proteinkinasehemmer
BRPI0417697A (pt) inibidores de protease de aspartila heterocìclicos
BRPI0617165A2 (pt) Compostos inibidores mek, composições farmacêuticas que os contem e métodos de uso dos mesmos
ATE371656T1 (de) Heteroaryl-pyrimidinderivate als jak-inhibitoren
CY1110385T1 (el) Χρηση αναστολεων της il-18 για τη θεραπεια και/ή προληψη της αθηροσκληρωσης
DE60214198D1 (de) Isoxazolyl-pyrimidines als inhibitoren von src- und lck-protein-kinasen
DE60312017D1 (de) Sulfonderivate zur hemmung von gamma-secretase
NO996578L (no) Urokinase-inhibitorer
NO20081843L (no) Farmasoytisk sammensetning for forbedret kognitiv funksjon
NO20040211L (no) Kombinasjon av en aldosteronreseptor for antagonist og en HMB COA-reduktaseinhibitor
DK1456380T3 (da) SMAD7-inhibitorer til behandling af CNS-sygdomme
ES2194202T3 (es) Compuestos polimorfos.
DE60140871D1 (de) Arylmethylamin-derivate zur verwendung als inhibitoren von tryptase
DE60323765D1 (de) Inhibitoren der 17 beta-hydroxysteroiddehydrogenase des typs 3 zur behandlung androgenabhängiger krankheiten
NO20060328L (no) Kombinasjon av mGluR2-antagonist og ACHE-inhibitor for behandiing av akutt og/eller kronisk neurologiske forstyrrelser
EE200300201A (et) Püranoonsete proteaasi inhibiitorite iseemulgeeruva kompositsiooni oraalne doos
ATE443044T1 (de) Tace inhibitoren
DK1007040T3 (da) Anvendelsen af phanquinon til behandlingen af Alzheimers sygdom
DE60134735D1 (de) Neue neurokinin-antagonisten zum gebrauch als arzneimittel